Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Boehringer Ingelheim
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Gruppo Oncologico del Nord-Ovest
BeiGene
Korea University Anam Hospital
The Netherlands Cancer Institute
The First Affiliated Hospital with Nanjing Medical University
Aurigene Discovery Technologies Limited
Imugene Limited
Zhejiang University
BeyondBio Inc.
ImmunityBio, Inc.
Cyteir Therapeutics, Inc.
Case Comprehensive Cancer Center
ImmunityBio, Inc.
ImmunityBio, Inc.
BeiGene
Sun Yat-sen University
ImmunityBio, Inc.
University of Oxford
ImmunityBio, Inc.
ImmunityBio, Inc.
Ludwig Institute for Cancer Research
Georgetown University
Zhejiang Cancer Hospital
Sumitomo Pharma America, Inc.
Korean Cancer Study Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute, Naples
EMD Serono
Henan Cancer Hospital
Fudan University
ChineseAMS
Silverback Therapeutics
PharmaEngine
SCRI Development Innovations, LLC
National Cancer Center Hospital East
Roswell Park Cancer Institute
Seoul St. Mary's Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
ChineseAMS
Zhongshan Hospital Xiamen University
M.D. Anderson Cancer Center
Asan Medical Center
Qingdao Zhixin Health Technology Co., Ltd.
University of Wisconsin, Madison
Seoul National University Hospital